Bausch + Lomb Advances Oral Dry AMD Treatment After Positive FDA Feedback

  • Bausch + Lomb's BL1243 (tonabersat) oral treatment for dry AMD received constructive FDA feedback on October 6, 2026.
  • Initial study design approved in principle; Phase 2 trials expected to start in 2027.
  • BL1243 leverages prior clinical experience with tonabersat in 2,100 patients, including a 63-participant DRCR Retina Network study.
  • Dry AMD affects the macula, leading to progressive vision loss, with limited current treatment options.

Bausch + Lomb's progress with BL1243 reflects the growing focus on developing non-invasive, oral therapies for chronic eye diseases. The FDA's constructive feedback underscores the need for earlier intervention in dry AMD, a condition with limited treatment options. The company's ability to leverage prior clinical data could accelerate development, but success hinges on demonstrating efficacy in a competitive ophthalmology market.

Clinical Execution
Whether Bausch + Lomb can successfully navigate the Phase 2 trial timeline and demonstrate efficacy in dry AMD patients.
Regulatory Pathway
The pace at which the FDA will review and potentially approve BL1243, given its novel oral administration route.
Market Differentiation
How BL1243's convenience and earlier intervention potential will position it against existing and emerging dry AMD treatments.